Comparison of Lower-risk MDS Patients With and Without Improvements in Fatigue Following Blood Transfusion Therapy

Myelodysplatic Syndromes Clinical Trial

— FITME  

Official title:

Fatigue in Myelodysplasic Patients : Why Blood Transfusion Does Not Systematically Improve Symptoms? (FITME Study)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04103359
• Other study ID #: 2019-0701
• Secondary ID: 2019-A01877-50
• Status: Terminated
• Phase: N/A
• Start date: October 20, 2020
• Est. completion date: October 20, 2020

Study information

• Verified date: May 2023
• Source: Centre Hospitalier Universitaire de Saint Etienne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

At present, it is unclear why some myelodysplastic patients (MDS) receiving blood transfusion therapy exhibit an increase in Hemoglobin (Hb) without a concurrent improvement in fatigue. Research is thus required to elucidate on why fatigue persists in some MDS patients in order to devise strategies to alleviate fatigue in "non-responders" to blood transfusion.

Description:

One hypothesis is that patients who exhibited persistent fatigue following a blood- transfusion- induced increase in Hb have an impaired ability to utilize oxygen at the peripheral level. This could be the consequence of impairments in vascular function, mediated by endothelial dysfunction as a result of transfusion-induced iron-overload and oxidative stress associated with the disease. Taking the current gaps in knowledge pertaining to MDS-related fatigue into account, the objective of this study is to improve understanding on the aetiology fatigue in MDS patients. To achieve this aim, the study will measure a comprehensive group of patient-reported and disease-related outcomes: i) prior to blood transfusion therapy when Hb levels are low and; ii) following blood transfusion therapy, when Hb levels have been increased. Results from the post-transfusion tests will be analyzed to determine which participants remain fatigued despite an increase in Hb, and which participants shown an improvement in fatigue.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: October 20, 2020
• Est. primary completion date: October 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient affiliated to a social security regimen or beneficiary of the same

• Signed written informed consent form

• Patient, = 18 years-old, with established diagnosis of myelodysplastic syndrome with low or intermediate-1 risk cytogenetic profile

• FACIT-F score = 34,

• Indication of blood transfusion.

Exclusion Criteria:

• Contra-indication to experimental procedures and/or physical exercise,

• Concomitant cancer diagnosis,

• Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent

• Refusing participation.

Related Conditions & MeSH terms

• Fatigue
• Myelodysplatic Syndromes

Intervention

Other:
• Physiological tests to measure fatigue level
Physiological tests to measure fatigue level

Locations

Country	Name	City	State
France	CHU de Saint-Etienne	Saint-Étienne

Sponsors (3)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Saint Etienne	Institut de Cancérologie de la Loire, Laboratoire Interuniversitaire de Biologie de la Motricité - Jean Monnet University Saint-Etienne

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of Fatigue using FACIT-F questionnaire	Measurement of Fatigue will be performed using FACIT-F questionnaire. This is a questionnaire with 13 questions about which the patient is positioned on a Likert scale ranging from 1 to 5 (1 = quite, 5 = not at all). By adding the answers, a score out of 65 is obtained. Unlike other scales the higher the score the less the patient is tired. As an indication, the non-sick average positions is 40.1 on this scale.	10 days